Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674 1682
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18067085 | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18240367 | TREATMENT OF SMC MEDIATED DISEASE | Non-Final OA | National University of Singapore |
| 17769188 | METHODS FOR MODULATING LEVEL OF EXPRESSION FROM GENE THERAPY EXPRESSION CASSETTE | Non-Final OA | Cornell University |
| 17748629 | Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha | Non-Final OA | Janssen Biotech, Inc. |
| 18451632 | Methods and Compositions for Treating Cancer | Non-Final OA | Omeros Corporation |
| 17107617 | METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS | Final Rejection | NXERA PHARMA UK LIMITED |
| 18372917 | IMMUNOGLOBULIN FUSION PROTEINS | Non-Final OA | UBI Pharma Inc. (UBIP) |
| 18372942 | METHOD FOR PRODUCING IMMUNOGLOBULIN FUSION PROTEINS | Non-Final OA | UBI Pharma Inc. (UBIP) |
| 18336792 | GLYCOPROTEIN HORMONE RECEPTOR MUTATIONS | Final Rejection | RSR Limited |
| 18098435 | DIAGNOSTIC ALGORITHMS FOR DETERMINING AND TREATING CLINICALLY SIGNIFICANT PROSTATE CANCER BASED ON SIALYLATED AND FUCOSYLATED PROSTATE SPECIFIC ANTIGEN | Non-Final OA | GLYCA INC |
| 17531916 | FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | Non-Final OA | Ablynx N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy